Ratings by Baird (Joel Beatty)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 6/30/2026 | Larimar Therapeutics | LRMR | Maintain | Outperform (N/A) |
|
Details | ||
| 6/26/2026 | Acadia Pharmaceuticals | ACAD | Maintain | Outperform (Outperform) |
|
Details | ||
| 5/13/2026 | Alkermes | ALKS | Maintain | Outperform (N/A) |
|
Details | ||
| 5/4/2026 | Axsome Therapeutics | AXSM | Maintain | Outperform (N/A) |
|
Details | ||
| 5/1/2026 | Axsome Therapeutics | AXSM | Maintain | Outperform (N/A) |
|
Details | ||
| 4/28/2026 | e.l.f. Beauty | ELF | Maintain | Outperform (N/A) |
|
Details | ||
| 4/7/2026 | Denali Therapeutics Inc. | DNLI | Maintain | Outperform (N/A) |
|
Details | ||
| 3/26/2026 | Denali Therapeutics Inc. | DNLI | Maintain | Outperform (N/A) |
|
Details | ||
| 3/9/2026 | Dianthus Therapeutics | DNTH | Maintain | Outperform (N/A) |
|
Details | ||
| 3/6/2026 | Contineum Therapeutics | CTNM | Maintain | Outperform (N/A) |
|
Details | ||
| 2/13/2026 | Ultragenyx Pharma | RARE | Maintain | Outperform (N/A) |
|
Details | ||
| 2/13/2026 | Bright Minds Biosciences Inc. | DRUG | Maintain | Outperform (N/A) |
|
Details | ||
| 2/5/2026 | e.l.f. Beauty | ELF | Maintain | Outperform (N/A) |
|
Details | ||
| 1/13/2026 | Axsome Therapeutics | AXSM | Maintain | Outperform (N/A) |
|
Details | ||
| 12/31/2025 | Axsome Therapeutics | AXSM | Maintain | Outperform (N/A) |
|
Details | ||
| 12/29/2025 | Ultragenyx Pharma | RARE | Maintain | Outperform (N/A) |
|
Details | ||
| 12/9/2025 | Confluent Inc | CFLT | Maintain | Neutral (N/A) |
|
Details | ||
| 11/24/2025 | Contineum Therapeutics | CTNM | Maintain | Outperform (N/A) |
|
Details | ||
| 11/18/2025 | Jazz Pharmaceuticals | JAZZ | Maintain | Outperform (N/A) |
|
Details | ||
| 11/7/2025 | Bright Minds Biosciences Inc. | DRUG | Maintain | Outperform (N/A) |
|
Details | ||
| 11/6/2025 | e.l.f. Beauty | ELF | Maintain | Outperform (N/A) |
|
Details | ||
| 11/5/2025 | PTC Therapeutics | PTCT | Maintain | Outperform (N/A) |
|
Details | ||
| 10/31/2025 | argenx SE | ARGX | Maintain | Outperform (N/A) |
|
Details | ||
| 10/28/2025 | Confluent Inc | CFLT | Maintain | Neutral (N/A) |
|
Details | ||
| 10/23/2025 | Alkermes | ALKS | Maintain | Outperform (N/A) |
|
Details | ||
| 10/16/2025 | Amylyx Pharmaceuticals inc. | AMLX | Maintain | Outperform (N/A) |
|
Details | ||
| 9/30/2025 | Larimar Therapeutics | LRMR | Maintain | Outperform (N/A) |
|
Details | ||
| 9/24/2025 | Acadia Pharmaceuticals | ACAD | Maintain | Outperform (N/A) |
|
Details | ||
| 9/9/2025 | Dianthus Therapeutics | DNTH | Maintain | Outperform (N/A) |
|
Details | ||
| 8/13/2025 | Editas Medicine | EDIT | Maintain | Outperform (N/A) |
|
Details | ||
| 8/8/2025 | PTC Therapeutics | PTCT | Maintain | Outperform (N/A) |
|
Details | ||
| 8/7/2025 | Jazz Pharmaceuticals | JAZZ | Maintain | Outperform (N/A) |
|
Details | ||
| 8/1/2025 | argenx SE | ARGX | Maintain | Outperform (N/A) |
|
Details | ||
| 7/31/2025 | Confluent Inc | CFLT | Maintain | Neutral (N/A) |
|
Details | ||
| 6/20/2025 | Sage Therapeutics | SAGE | Maintain | Neutral (N/A) |
|
Details | ||
| 6/10/2025 | Axsome Therapeutics | AXSM | Maintain | Outperform (N/A) |
|
Details | ||
| 6/6/2025 | e.l.f. Beauty | ELF | Maintain | Outperform (N/A) |
|
Details | ||
| 6/3/2025 | Blueprint Medicines | BPMC | Maintain | Outperform (N/A) |
|
Details | ||
| 5/19/2025 | Acadia Pharmaceuticals | ACAD | Maintain | Outperform (N/A) |
|
Details | ||
| 5/16/2025 | Neurogene | NGNE | Downgrade | Neutral (Outperform) |
15.22 (32.56) |
113.93% | Details | |
| 5/14/2025 | e.l.f. Beauty | ELF | Maintain | Outperform (N/A) |
|
Details | ||
| 5/13/2025 | Editas Medicine | EDIT | Maintain | Outperform (N/A) |
|
Details | ||
| 5/13/2025 | Dianthus Therapeutics | DNTH | Maintain | Outperform (N/A) |
|
Details | ||
| 5/13/2025 | argenx SE | ARGX | Upgrade | Outperform (Neutral) |
549.65 (851.42) |
54.9% | Details | |
| 5/8/2025 | Denali Therapeutics Inc. | DNLI | Maintain | Outperform (N/A) |
|
Details | ||
| 5/7/2025 | PTC Therapeutics | PTCT | Maintain | Outperform (N/A) |
|
Details | ||
| 5/7/2025 | Jazz Pharmaceuticals | JAZZ | Maintain | Outperform (N/A) |
|
Details | ||
| 5/6/2025 | Axsome Therapeutics | AXSM | Maintain | Outperform (N/A) |
|
Details | ||
| 5/5/2025 | Praxis Precision Medicines Inc. | PRAX | Maintain | Outperform (N/A) |
|
Details | ||
| 5/2/2025 | Alkermes | ALKS | Maintain | Outperform (N/A) |
|
Details | ||
| 5/1/2025 | Confluent Inc | CFLT | Maintain | Neutral (N/A) |
|
Details | ||
| 4/14/2025 | e.l.f. Beauty | ELF | Maintain | Outperform (N/A) |
|
Details | ||
| 3/25/2025 | Neurogene | NGNE | Maintain | Outperform (N/A) |
|
Details | ||
| 3/25/2025 | Larimar Therapeutics | LRMR | Maintain | Outperform (N/A) |
|
Details | ||
| 3/7/2025 | MindMed | MNMD | Maintain | Outperform (N/A) |
|
Details | ||
| 3/7/2025 | Contineum Therapeutics | CTNM | Maintain | Outperform (N/A) |
|
Details | ||
| 3/4/2025 | argenx SE | ARGX | Maintain | Neutral (N/A) |
|
Details | ||
| 3/3/2025 | Praxis Precision Medicines Inc. | PRAX | Maintain | Outperform (N/A) |
|
Details | ||
| 3/3/2025 | Catalyst Pharmaceutical Partners | CPRX | Maintain | Outperform (N/A) |
|
Details | ||
| 3/3/2025 | Axsome Therapeutics | AXSM | Maintain | Outperform (N/A) |
|
Details | ||
| 2/26/2025 | Jazz Pharmaceuticals | JAZZ | Maintain | Outperform (N/A) |
|
Details | ||
| 2/14/2025 | Blueprint Medicines | BPMC | Maintain | Outperform (N/A) |
|
Details | ||
| 2/7/2025 | e.l.f. Beauty | ELF | Maintain | Outperform (N/A) |
|
Details | ||
| 2/4/2025 | Catalyst Pharmaceutical Partners | CPRX | New Coverage | Outperform (N/A) |
22.56 (31.50) |
39.63% | Details | |
| 2/3/2025 | Axsome Therapeutics | AXSM | Maintain | Outperform (N/A) |
|
Details | ||
| 1/28/2025 | Leap Therapeutics | LPTX | Downgrade | Neutral (Outperform) |
2.25 (2.06) |
-8.44% | Details | |
| 1/13/2025 | Intra-Cellular Therapies | ITCI | Downgrade | Neutral (Outperform) |
94.87 (131.87) |
39% | Details | |
| 1/7/2025 | Denali Therapeutics Inc. | DNLI | New Coverage | Outperform (N/A) |
21.26 (25.74) |
21.07% | Details | |
| 12/30/2024 | Axsome Therapeutics | AXSM | Maintain | Outperform (N/A) |
|
Details | ||
| 12/17/2024 | Larimar Therapeutics | LRMR | Maintain | Outperform (N/A) |
|
Details | ||
| 12/13/2024 | Confluent Inc | CFLT | Maintain | Neutral (N/A) |
|
Details | ||
| 12/13/2024 | Editas Medicine | EDIT | Maintain | Outperform (N/A) |
|
Details | ||
| 12/3/2024 | PTC Therapeutics | PTCT | Maintain | Outperform (N/A) |
|
Details | ||
| 11/27/2024 | Acadia Pharmaceuticals | ACAD | Maintain | Outperform (Outperform) |
|
Details | ||
| 11/27/2024 | PTC Therapeutics | PTCT | Maintain | Outperform (N/A) |
|
Details | ||
| 11/26/2024 | Bright Minds Biosciences Inc. | DRUG | New Coverage | Outperform (N/A) |
35.33 (66.65) |
88.65% | Details | |
| 11/19/2024 | Neurogene | NGNE | Maintain | Outperform (N/A) |
|
Details | ||
| 11/18/2024 | Jazz Pharmaceuticals | JAZZ | Maintain | Outperform (N/A) |
|
Details | ||
| 11/18/2024 | Amylyx Pharmaceuticals inc. | AMLX | Upgrade | Outperform (Neutral) |
5.02 (17.97) |
257.97% | Details | |
| 11/15/2024 | Immutep Limited | IMMP | Maintain | Outperform (N/A) |
|
Details | ||
| 11/13/2024 | Axsome Therapeutics | AXSM | Maintain | Outperform (N/A) |
|
Details | ||
| 11/12/2024 | Neurogene | NGNE | Maintain | Outperform (N/A) |
|
Details | ||
| 11/8/2024 | PTC Therapeutics | PTCT | Maintain | Outperform (N/A) |
|
Details | ||
| 11/1/2024 | argenx SE | ARGX | Downgrade | Neutral (Outperform) |
551.71 (916.80) |
66.17% | Details | |
| 10/31/2024 | Confluent Inc | CFLT | Maintain | Neutral (N/A) |
|
Details | ||
| 10/22/2024 | Editas Medicine | EDIT | Maintain | Outperform (N/A) |
|
Details | ||
| 10/22/2024 | Contineum Therapeutics | CTNM | New Coverage | Outperform (N/A) |
16.38 (15.53) |
-5.19% | Details | |
| 10/21/2024 | e.l.f. Beauty | ELF | Maintain | Outperform (N/A) |
|
Details | ||
| 10/14/2024 | Longboard Pharmaceuticals Inc | LBPH | Downgrade | Neutral (Outperform) |
38.90 (59.98) |
54.19% | Details | |
| 10/10/2024 | Alkermes | ALKS | Maintain | Outperform (Outperform) |
|
Details | ||
| 10/9/2024 | PTC Therapeutics | PTCT | Maintain | Outperform (Outperform) |
|
Details | ||
| 10/9/2024 | Sage Therapeutics | SAGE | Maintain | Neutral (N/A) |
|
Details | ||
| 10/7/2024 | Dianthus Therapeutics | DNTH | Maintain | Outperform (Outperform) |
|
Details | ||
| 9/27/2024 | PTC Therapeutics | PTCT | Maintain | Outperform (Outperform) |
|
Details | ||
| 9/25/2024 | argenx SE | ARGX | Maintain | Outperform (Outperform) |
|
Details | ||
| 9/17/2024 | Longboard Pharmaceuticals Inc | LBPH | Maintain | Outperform (Outperform) |
|
Details | ||
| 9/9/2024 | Longboard Pharmaceuticals Inc | LBPH | Maintain | Outperform (Outperform) |
|
Details | ||
| 9/9/2024 | Calidi Biotherapeutics Inc | CLDI | Maintain | Outperform (N/A) |
|
Details | ||
| 9/6/2024 | Longboard Pharmaceuticals Inc | LBPH | Maintain | Outperform (Outperform) |
|
Details | ||
| 9/4/2024 | Confluent Inc | CFLT | New Coverage | Neutral (N/A) |
21.22 (30.99) |
46.04% | Details | |
| 9/4/2024 | Larimar Therapeutics | LRMR | New Coverage | Outperform (N/A) |
7.91 (3.29) |
-58.41% | Details | |
| 9/4/2024 | PTC Therapeutics | PTCT | New Coverage | Outperform (N/A) |
35.32 (85.44) |
141.9% | Details | |
| 8/9/2024 | e.l.f. Beauty | ELF | Maintain | Outperform (N/A) |
|
Details | ||
| 8/2/2024 | Blueprint Medicines | BPMC | Maintain | Outperform (N/A) |
|
Details | ||
| 8/1/2024 | Jazz Pharmaceuticals | JAZZ | Maintain | Outperform (N/A) |
|
Details | ||
| 7/29/2024 | argenx SE | ARGX | Maintain | Outperform (N/A) |
|
Details | ||
| 7/26/2024 | Dianthus Therapeutics | DNTH | New Coverage | Outperform (N/A) |
27.83 (93.34) |
235.39% | Details | |
| 7/25/2024 | Sage Therapeutics | SAGE | Maintain | Neutral (N/A) |
|
Details | ||
| 7/25/2024 | Alkermes | ALKS | Maintain | Outperform (N/A) |
|
Details | ||
| 7/18/2024 | e.l.f. Beauty | ELF | Upgrade | Outperform (Neutral) |
189.02 (73.49) |
-61.12% | Details | |
| 7/11/2024 | Longboard Pharmaceuticals Inc | LBPH | Maintain | Outperform (N/A) |
|
Details | ||
| 6/27/2024 | Immutep Limited | IMMP | Maintain | Outperform (N/A) |
|
Details | ||
| 6/11/2024 | Neurogene | NGNE | New Coverage | Outperform (N/A) |
37.88 (32.56) |
-14.04% | Details | |
| 6/5/2024 | MindMed | MNMD | Maintain | Outperform (N/A) |
|
Details | ||
| 5/31/2024 | Ultragenyx Pharma | RARE | Maintain | Outperform (N/A) |
|
Details | ||
| 5/29/2024 | MindMed | MNMD | New Coverage | Outperform (N/A) |
8.23 (15.02) |
82.5% | Details | |
| 5/29/2024 | Sage Therapeutics | SAGE | New Coverage | Neutral (N/A) |
11.78 (8.68) |
-26.32% | Details | |
| 5/15/2024 | Calidi Biotherapeutics Inc | CLDI | Maintain | Outperform (N/A) |
|
Details | ||
| 5/9/2024 | Acadia Pharmaceuticals | ACAD | Maintain | Outperform (N/A) |
|
Details | ||
| 5/7/2024 | Axsome Therapeutics | AXSM | Maintain | Outperform (N/A) |
|
Details | ||
| 5/1/2024 | Praxis Precision Medicines Inc. | PRAX | New Coverage | Outperform (N/A) |
56.86 (313.50) |
451.35% | Details | |
| 5/1/2024 | Longboard Pharmaceuticals Inc | LBPH | New Coverage | Outperform (N/A) |
21.23 (59.98) |
182.52% | Details | |
| 4/30/2024 | Geron Corporation | GERN | Downgrade | Neutral (Outperform) |
3.79 (1.44) |
-62.01% | Details | |
| 4/17/2024 | Intra-Cellular Therapies | ITCI | Maintain | Outperform (N/A) |
|
Details | ||
| 4/11/2024 | Nurix | NRIX | Maintain | Outperform (N/A) |
|
Details | ||
| 4/11/2024 | Amylyx Pharmaceuticals inc. | AMLX | Maintain | Neutral (N/A) |
|
Details | ||
| 3/21/2024 | Calidi Biotherapeutics Inc | CLDI | Maintain | Outperform (N/A) |
|
Details | ||
| 3/19/2024 | Leap Therapeutics | LPTX | Maintain | Outperform (N/A) |
|
Details | ||
| 3/19/2024 | Axsome Therapeutics | AXSM | New Coverage | Outperform (N/A) |
75.54 (242.60) |
221.15% | Details | |
| 3/19/2024 | Alkermes | ALKS | New Coverage | Outperform (N/A) |
28.75 (55.14) |
91.79% | Details | |
| 3/12/2024 | Acadia Pharmaceuticals | ACAD | Maintain | Outperform (N/A) |
|
Details | ||
| 3/11/2024 | Amylyx Pharmaceuticals inc. | AMLX | Downgrade | Neutral (Outperform) |
18.97 (5.02) |
-73.54% | Details | |
| 3/1/2024 | argenx SE | ARGX | Maintain | Outperform (N/A) |
|
Details | ||
| 2/29/2024 | Geron Corporation | GERN | Maintain | Outperform (N/A) |
|
Details | ||
| 2/7/2024 | e.l.f. Beauty | ELF | Maintain | Neutral (N/A) |
|
Details | ||
| 1/30/2024 | Ultragenyx Pharma | RARE | Maintain | Outperform (N/A) |
|
Details | ||
| 1/30/2024 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Outperform (N/A) |
|
Details | ||
| 1/30/2024 | e.l.f. Beauty | ELF | New Coverage | Neutral (N/A) |
157.14 (189.02) |
20.29% | Details | |
| 1/30/2024 | Acadia Pharmaceuticals | ACAD | New Coverage | Outperform (N/A) |
26.94 (25.77) |
-4.34% | Details | |
| 1/16/2024 | Ambrx Biopharma | AMAM | Downgrade | Neutral (Outperform) |
27.97 (28.00) |
0.11% | Details | |
| 1/3/2024 | Intra-Cellular Therapies | ITCI | New Coverage | Outperform (N/A) |
71.62 (131.87) |
84.12% | Details | |
| 1/3/2024 | Jazz Pharmaceuticals | JAZZ | New Coverage | Outperform (N/A) |
123.00 (244.17) |
98.51% | Details | |
| 1/3/2024 | Amylyx Pharmaceuticals inc. | AMLX | New Coverage | Outperform (N/A) |
14.72 (17.97) |
22.08% | Details | |
| 12/12/2023 | Cogent | COGT | Maintain | Outperform (N/A) |
|
Details | ||
| 11/29/2023 | argenx SE | ARGX | Maintain | Outperform (N/A) |
|
Details | ||
| 11/17/2023 | Ambrx Biopharma | AMAM | Maintain | Outperform (N/A) |
|
Details | ||
| 11/14/2023 | Leap Therapeutics | LPTX | Maintain | Outperform (N/A) |
|
Details | ||
| 10/13/2023 | Nurix | NRIX | Maintain | Outperform (N/A) |
|
Details | ||
| 10/9/2023 | Calidi Biotherapeutics Inc | CLDI | New Coverage | Outperform (N/A) |
3.06 (0.15) |
-95.1% | Details | |
| 10/3/2023 | Syndax Pharmaceuticals | SNDX | Maintain | Outperform (N/A) |
|
Details | ||
| 9/8/2023 | Vaxxinity | VAXX | New Coverage | Outperform (N/A) |
1.86 (0.01) |
-99.46% | Details | |
| 8/15/2023 | Tracon Pharmaceuticals | TCON | Maintain | Outperform (N/A) |
|
Details | ||
| 8/15/2023 | Leap Therapeutics | LPTX | Maintain | Outperform (N/A) |
|
Details | ||
| 8/7/2023 | IGM Biosciences | IGMS | Maintain | Outperform (N/A) |
|
Details | ||
| 8/3/2023 | Immutep Limited | IMMP | New Coverage | Outperform (N/A) |
2.17 (2.76) |
27.19% | Details | |
| 7/18/2023 | argenx SE | ARGX | Maintain | Outperform (N/A) |
|
Details | ||
| 6/5/2023 | Ambrx Biopharma | AMAM | Maintain | Outperform (N/A) |
|
Details | ||
| 6/1/2023 | INmune Bio Inc. | INMB | New Coverage | Outperform (N/A) |
7.87 (1.67) |
-78.78% | Details | |
| 5/23/2023 | Chimerix | CMRX | New Coverage | Outperform (N/A) |
1.21 (8.54) |
605.79% | Details | |
| 5/11/2023 | Tracon Pharmaceuticals | TCON | Maintain | Outperform (N/A) |
|
Details | ||
| 5/2/2023 | BeyondSpring Inc. | BYSI | Maintain | Outperform (N/A) |
|
Details | ||
| 4/28/2023 | Cogent | COGT | New Coverage | Outperform (N/A) |
10.78 (39.44) |
265.86% | Details | |
| 4/27/2023 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Outperform (N/A) |
|
Details | ||
| 4/13/2023 | Pliant Therapeutics | PLRX | New Coverage | Outperform (N/A) |
26.37 (1.15) |
-95.64% | Details | |
| 4/5/2023 | Ambrx Biopharma | AMAM | Maintain | Outperform (N/A) |
|
Details | ||
| 3/27/2023 | Leap Therapeutics | LPTX | Maintain | Outperform (N/A) |
|
Details | ||
| 3/15/2023 | BeyondSpring Inc. | BYSI | Maintain | Outperform (N/A) |
|
Details | ||
| 3/3/2023 | Ambrx Biopharma | AMAM | Maintain | Outperform (N/A) |
|
Details | ||
| 2/17/2023 | Ultragenyx Pharma | RARE | Maintain | Outperform (N/A) |
|
Details | ||
| 2/7/2023 | Arrowhead Pharma | ARWR | Maintain | Outperform (N/A) |
|
Details | ||
| 11/10/2022 | Arcturus Therapeutics | ARCT | Downgrade | Underperform (Neutral) |
22.82 (7.35) |
-67.79% | Details | |
| 11/3/2022 | Ultragenyx Pharma | RARE | Upgrade | Outperform (Neutral) |
40.59 (33.70) |
-16.97% | Details | |
| 11/3/2022 | Editas Medicine | EDIT | Maintain | Outperform (N/A) |
|
Details | ||
| 7/29/2022 | argenx SE | ARGX | Downgrade | Neutral (Outperform) |
357.86 (551.71) |
54.17% | Details | |
| 5/11/2022 | Arrowhead Pharma | ARWR | Upgrade | Outperform (Neutral) |
32.72 (86.55) |
164.52% | Details | |
| 5/11/2022 | Arcturus Therapeutics | ARCT | Upgrade | Neutral (Underperform) |
16.61 (7.35) |
-55.75% | Details | |
| 5/10/2022 | Syndax Pharmaceuticals | SNDX | Maintain | Outperform (N/A) |
|
Details | ||
| 4/7/2022 | Ambrx Biopharma | AMAM | New Coverage | Outperform (N/A) |
4.07 (28.00) |
587.96% | Details | |
| 4/4/2022 | IGM Biosciences | IGMS | Maintain | Outperform (N/A) |
|
Details | ||
| 3/3/2022 | Vir Biotechnology | VIR | Upgrade | Neutral (Underperform) |
24.13 (10.02) |
-58.47% | Details | |
| 2/23/2022 | Tracon Pharmaceuticals | TCON | New Coverage | Outperform (N/A) |
2.41 (1.43) |
-40.66% | Details | |
| 12/21/2021 | Vir Biotechnology | VIR | Downgrade | Underperform (Neutral) |
53.92 (10.02) |
-81.42% | Details | |
| 11/17/2021 | Vir Biotechnology | VIR | Maintain | Neutral (N/A) |
|
Details | ||
| 11/2/2021 | Geron Corporation | GERN | New Coverage | Outperform (N/A) |
1.54 (1.44) |
-6.49% | Details | |
| 9/9/2021 | BeyondSpring Inc. | BYSI | New Coverage | Outperform (N/A) |
23.46 (1.79) |
-92.37% | Details | |
| 8/10/2021 | Arcturus Therapeutics | ARCT | Downgrade | Underperform (Neutral) |
48.24 (7.35) |
-84.76% | Details | |
| 6/4/2021 | Syndax Pharmaceuticals | SNDX | New Coverage | Outperform (N/A) |
18.07 (22.08) |
22.19% | Details | |
| 6/4/2021 | Nurix | NRIX | New Coverage | Neutral (N/A) |
29.42 (24.69) |
-16.08% | Details | |
| 6/4/2021 | Leap Therapeutics | LPTX | New Coverage | Outperform (N/A) |
1.62 (2.25) |
38.89% | Details | |
| 6/4/2021 | IGM Biosciences | IGMS | New Coverage | Outperform (N/A) |
80.87 (1.27) |
-98.43% | Details | |
| 6/4/2021 | Atreca Inc. | BCEL | New Coverage | Outperform (N/A) |
9.27 (0.09) |
-99.03% | Details | |
| 6/4/2021 | argenx SE | ARGX | New Coverage | Outperform (N/A) |
268.12 (916.80) |
241.94% | Details | |
| 6/4/2021 | Arcturus Therapeutics | ARCT | New Coverage | Neutral (N/A) |
31.13 (7.35) |
-76.39% | Details | |
| 6/4/2021 | Vir Biotechnology | VIR | New Coverage | Neutral (N/A) |
44.48 (10.02) |
-77.47% | Details | |
| 6/4/2021 | Editas Medicine | EDIT | New Coverage | Outperform (N/A) |
35.04 (3.65) |
-89.58% | Details | |
| 6/4/2021 | Ideaya Biosciences | IDYA | New Coverage | Outperform (N/A) |
20.18 (39.37) |
95.09% | Details | |
| 6/4/2021 | Blueprint Medicines | BPMC | New Coverage | Outperform (N/A) |
87.13 (129.46) |
48.58% | Details | |
| 6/4/2021 | Arrowhead Pharma | ARWR | New Coverage | Neutral (N/A) |
72.24 (86.55) |
19.81% | Details | |
| 6/4/2021 | BioMarin Pharmaceutical Inc. | BMRN | New Coverage | Outperform (N/A) |
77.35 (80.40) |
3.94% | Details | |
| 6/4/2021 | Ultragenyx Pharma | RARE | New Coverage | Neutral (N/A) |
97.70 (33.70) |
-65.51% | Details |
